BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 20121479)

  • 1. Proteomics in prostate cancer biomarker discovery.
    Larkin SE; Zeidan B; Taylor MG; Bickers B; Al-Ruwaili J; Aukim-Hastie C; Townsend PA
    Expert Rev Proteomics; 2010 Feb; 7(1):93-102. PubMed ID: 20121479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers of prostate cancer.
    Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
    Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary markers for prostate cancer.
    Downes MR; Byrne JC; Pennington SR; Dunn MJ; Fitzpatrick JM; Watson RW
    BJU Int; 2007 Feb; 99(2):263-8. PubMed ID: 17092277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for prostate cancer detection.
    Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
    J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics.
    Bharti A; Ma PC; Salgia R
    Mass Spectrom Rev; 2007; 26(3):451-66. PubMed ID: 17407130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK; Tyson DR
    Urol Oncol; 2006; 24(3):231-6. PubMed ID: 16678055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis of colorectal cancer: discovering novel biomarkers.
    Skandarajah AR; Moritz RL; Tjandra JJ; Simpson RJ
    Expert Rev Proteomics; 2005 Oct; 2(5):681-92. PubMed ID: 16209648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond prostate-specific antigen: alternate serum markers.
    Ramírez ML; Nelson EC; Evans CP
    Prostate Cancer Prostatic Dis; 2008; 11(3):216-29. PubMed ID: 18227856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
    Flaig TW; Nordeen SK; Lucia MS; Harrison GS; Glodé LM
    J Urol; 2007 Apr; 177(4):1229-37. PubMed ID: 17382696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic approaches in lung cancer biomarker development.
    Cho JY; Sung HJ
    Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B; Ball G; Rees R
    Vaccine; 2007 Sep; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
    Sardana G; Jung K; Stephan C; Diamandis EP
    J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomics: new technologies and clinical applications.
    Latterich M; Abramovitz M; Leyland-Jones B
    Eur J Cancer; 2008 Dec; 44(18):2737-41. PubMed ID: 18977654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer biomarkers: knowing the present and predicting the future.
    Chatterjee SK; Zetter BR
    Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic approaches for serum biomarker discovery in cancer.
    Maurya P; Meleady P; Dowling P; Clynes M
    Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.